John Godwin, M.D., who heads up the program, is a nationally known expert in leukemia and lymphoma and a member of the National Cancer Institute's Leukemia Steering Committee. He is actively involved in both research and patient care at Providence. Under his leadership, our multidisciplinary team offers patient-focused care, expert second opinions for complex cases, and cutting-edge research studies of the most promising agents. Many of our clinical trials are first-in-human studies of new immunotherapies aimed at maximizing the potential of the immune system to destroy tumors.
Currently, 20 clinical trials - of which most are immunotherapy studies - are open to patients with hematologic cancers. Here are five of them:
